8-K - Galectin Therapeutics Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Galectin Therapeutics reported a reduced net loss of $31.0 million for FY2025 and extended its cash runway to April 2027 via a $10 million credit line from its Chairman.

Key Takeaways

1Net loss applicable to common stockholders decreased to $31.0 million ($0.48/share) in FY2025 from $47.2 million ($0.76/share) in FY2024, driven by lower R&D costs.

2R&D expenses fell to $14.3 million in FY2025 from $36.6 million in FY2024, primarily due to the conclusion of the NAVIGATE clinical trial.

3The Company secured an additional $10 million line of credit from Chairman Dick Uihlein, extending the projected cash runway through April 2027.

4Unrestricted cash and cash equivalents totaled $17.7 million as of December 31, 2025, compared to $15.1 million in the prior year.

5NAVIGATE trial data showed belapectin reduced varices incidence by 49.3% in the per-protocol population; FDA meeting scheduled for Q2 2026.

Current Report Details

Event Type

Financial Results

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

2.02

is being furnished, not filed, pursuant to Item 2.02 of Form 8-K. Accordingly, the information in Item 2.02 of this report, including the Press Release attached

Financial Results

9.01

| Financial Statements and Exhibits. | |---|---| (d) Exhibits. Exhibit Number: 99.1 | Description: Press Release dated March 31, 2026 Exhibit Number: 104 | Desc

Exhibits Only

Source Document

Results of Operations

Year Ended December 31, 2025

Metric	Value	Basis	Prior Period
Research and Development Expenses	$14.29	GAAP	$36.57
General and Administrative Expenses	$5.80	GAAP	$5.86
Net Loss	$-30.84	GAAP	$-47.05
Net Loss Applicable to Common Stockholders	$-30.97	GAAP	$-47.20
Net Loss Per Share	$-0.48	GAAP	$-0.76

Transaction Details

Debt / Financing

Instrument: Line of Credit
Principal: 10000000
Use of Proceeds: To fund future operations and extend cash runway.

Exhibits (2)

8-K

99.1

EXHIBIT 99.1